597 related articles for article (PubMed ID: 23398530)
1. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy and safety of empagliflozin addition to insulin and oral antidiabetic medication (OAD) regimen in poorly controlled type 2 diabetes and obese patients.
Sharif H; Sheikh SS; Salman A; Jawed Z; Karim I; Sohail T; Mohsin N
Pak J Pharm Sci; 2024 Mar; 37(2):357-366. PubMed ID: 38767103
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
[TBL] [Abstract][Full Text] [Related]
4. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Care; 2013 Nov; 36(11):3396-404. PubMed ID: 23963895
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Inzucchi SE; Davies MJ; Khunti K; Trivedi P; George JT; Zwiener I; Johansen OE; Sattar N
Diabetes Obes Metab; 2021 Feb; 23(2):425-433. PubMed ID: 33084149
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
Salsali A; Kim G; Woerle HJ; Broedl UC; Hantel S
Diabetes Obes Metab; 2016 Oct; 18(10):1034-40. PubMed ID: 27376831
[TBL] [Abstract][Full Text] [Related]
9. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Rosenstock J; Cefalu WT; Lapuerta P; Zambrowicz B; Ogbaa I; Banks P; Sands A
Diabetes Care; 2015 Mar; 38(3):431-8. PubMed ID: 25216510
[TBL] [Abstract][Full Text] [Related]
10. A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
Sohn TS; Han KA; Kim Y; Lee BW; Chon S; Jeong IK; Hong EG; Son JW; Na J; Cho JM; In Cho S; Huh W; Yoon KH
Diabetes Obes Metab; 2024 Jun; 26(6):2248-2256. PubMed ID: 38456558
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Xie L; Han J; Cheng Z; Liu D; Liu J; Xu C; Sun W; Li Q; Bian F; Zhang W; Chen J; Zhu Q; Thurber TK; Lock JP; Zhang B
J Diabetes; 2024 Apr; 16(4):e13526. PubMed ID: 38584148
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Kim NH; Lim S; Kwak SH; Moon MK; Moon JS; Lee YH; Cho HC; Lee J; Kim SG
BMJ Open; 2018 Sep; 8(9):e022448. PubMed ID: 30249630
[TBL] [Abstract][Full Text] [Related]
14. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
[TBL] [Abstract][Full Text] [Related]
15. A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
Neeland IJ; Salahuddin U; McGuire DK
Expert Opin Drug Saf; 2016; 15(3):393-402. PubMed ID: 26695551
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
Sinclair AJ; Bode B; Harris S; Vijapurkar U; Shaw W; Desai M; Meininger G
J Am Geriatr Soc; 2016 Mar; 64(3):543-52. PubMed ID: 27000327
[TBL] [Abstract][Full Text] [Related]
17. Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
Gohari S; Reshadmanesh T; Khodabandehloo H; Fathi M; Ahangar H; Arsang-Jang S; Ismail-Beigi F; Ghanbari S; Dadashi M; Muhammadi MJ; Gohari S; Ghaffari S
BMC Cardiovasc Disord; 2021 Jun; 21(1):318. PubMed ID: 34193056
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Færch K; Amadid H; Nielsen LB; Ried-Larsen M; Karstoft K; Persson F; Jørgensen ME
BMJ Open; 2017 Jun; 7(5):e013802. PubMed ID: 28592573
[TBL] [Abstract][Full Text] [Related]
19. Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post-authorization safety study.
Fazeli Farsani S; Iglay K; Zhang L; Niyonkuru C; Nessralla L; Girman CJ
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5800. PubMed ID: 38719731
[TBL] [Abstract][Full Text] [Related]
20. A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial.
Guo L; Xi Y; Jin W; Yuan H; Qin G; Chen S; Zhang L; Liu Y; Cheng X; Liu W; Yu D
JAMA Netw Open; 2024 Jun; 7(6):e2416786. PubMed ID: 38904963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
